Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To investigate the clinical efficacy of various methods such as bone transport, fibular autograft alone or combined with skin flap in the treatment of segmental infectious bone defects in lower extremities. Methods: From June 2006 to June2012, 43 male and 20 female patients with segmental infectious bone defect in lower extremities in accordance with the inclusion criteria were observed under a retrospective study. All the patients were treated at one-stage after a strict debridement. Various types of methods were used to repair the defects: bone transport were used in 28 cases, fibular autografts were used in 35 cases including 14 cases of simple fibular autografts, 9 cases of fibular with skin flaps and 12 cases of fibular grafts combined with anterior lateral thigh flaps. Results: All the patients were followed up 6 to 26 months, mean 17.2 months. Except 3 cases of uncontrolled infection, the limb deformities or bone defects of other 60 patients were repaired successfully. In these 60 cases, the load line of force, physical appearance and function recovered, no serious complications were found. The limbs function of all the patients were evaluated by Johner-Wruhs score, 28 cases were excellent, 23 cases were good,6 cases were fair and 6 cases were poor, the total excellent and good rate was 81.0%.Conclusion: Segmental infectious bone defect in lower extremities always involved the injury of bone, muscle, skin and soft tissue, the treatments should carry out according to the disease to save the patients’ limb function, reduce the number of operations, shorten the treatment time and get the cost-saving treatment. [ABSTRACT FROM AUTHOR]

Objective: To investigate the cytotoxicity of vancomycin(Van)/calcium phosphate cement(CPC) composite materials on rat bone marrow mesenchymal stem cells(BMSCs). Methods: Primary BMSCs were isolated, cultured and identified. The cells were incubated with different concentrations(containing 0%, 1%, 5%, 10% Van) of Van/CPC composite materials. The cell viability of BMSCs was measured by CCK-8 method, and the cell apoptosis was detected by TUNEL method and the cell morphology was observed-by scanning electron microscope(SEM). Results: 5% and 10% Van/CPC composite materials could significantly inhibit the proliferation of BMSCs(P<0.05), and increase apoptosis(P<0.05) and lead to higher cytotoxicity.1% Van/CPC exerted no obvious effect on the BMSCs compared to the blank control. Conclusion: Low concentration of Van/CPC had no cytotoxicity on rat and BMSCs performed good biocompatibility. [ABSTRACT FROM AUTHOR]